Mesenchymal stem cells recruited by active TGFβ contribute to osteogenic vascular calcification

Stem Cells and Development

Volumn 23, Issue 12, 2014, Pages 1392-1404

  Wang, Weishan ^a,b   Li, Changjun ^a,c   Pang, Lijuan ^a   Shi, Chenhui ^a,b   Guo, Fengjing ^b   Chen, Anmin ^b   Cao, Xu ^c   Wan, Mei ^c  

^a SHIHEZI UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; LOW DENSITY LIPOPROTEIN RECEPTOR; NESTIN; NEUTRALIZING ANTIBODY; OSTEOCALCIN; STEM CELL ANTIGEN 1; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CIRCULATION; COLONY FORMING UNIT; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; FIBROBLAST; LIPID DIET; MALE; MESENCHYMAL STEM CELL; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PARABIOSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; BLOOD VESSEL CALCIFICATION; EXTRACELLULAR MATRIX; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; NEOINTIMA; PATHOLOGY;

ANIMALS; AORTA; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; MESENCHYMAL STROMAL CELLS; MICE; NEOINTIMA; OSTEOBLASTS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, LDL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CALCIFICATION;

EID: 84902125352     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0528     Document Type: Article

References (63)

1. Demer LL and Y Tintut. (2008). Vascular calcification: pathobiology of a multifaceted disease. Circulation 117: 2938-2948.
2. Hamirani YS, S Pandey, JJ Rivera, C Ndumele, MJ Budoff, RS Blumenthal and K Nasir. (2008). Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201:1-7.
3. Sage A, Y Tintut, A Garfinkel and L Demer. (2009). Systems biology of vascular calcification. Trends Cardiovasc Med 19:118-123.
4. Blacher J, AP Guerin, B Pannier, SJ Marchais and GM London. (2001). Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942.
5. Lutgens E, RJ van Suylen, BC Faber, MJ Gijbels, PM Eurlings, AP Bijnens, KB Cleutjens, S Heeneman and MJ Daemen. (2003). Atherosclerotic plaque rupture: local or systemic process? Arterioscler Thromb Vasc Biol 23:2123-2130.
6. Abedin M, Y Tintut and LL Demer. (2004). Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161-1170.
7. Sage AP, Y Tintut and LL Demer. (2010). Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 7:528-536.
8. Shao JS, SL Cheng, J Sadhu and DA Towler. (2010). Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 55:579-592.
9. Giachelli CM. (2004). Vascular calcification mechanisms. J Am Soc Nephrol 15:2959-2964.
10. Guzman RJ. (2007). Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg 45 Suppl A:A57-A63.
11. Johnson RC, JA Leopold and J Loscalzo. (2006). Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 99:1044-1059.
12. Speer MY, HY Yang, T Brabb, E Leaf, A Look, WL Lin, A Frutkin, D Dichek and CM Giachelli. (2009). Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 104: 733-741.
13. Tintut Y, Z Alfonso, T Saini, K Radcliff, K Watson, K Bostrom and LL Demer. (2003). Multilineage potential of cells from the artery wall. Circulation 108:2505-2510.
14. Farrington-Rock C, NJ Crofts, MJ Doherty, BA Ashton, C Griffin-Jones and AE Canfield. (2004). Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 110:2226-2232.
15. Pal SN, C Rush, A Parr, CA Van and J Golledge. (2010). Osteocalcin positive mononuclear cells are associated with the severity of aortic calcification. Atherosclerosis 210: 88-93.
16. Pal SN, P Clancy and J Golledge. (2011). Circulating concentrations of stem-cell-mobilizing cytokines are associated with levels of osteoprogenitor cells and aortic calcification severity. Circ J 75:1227-1234.
17. Pal SN and J Golledge. (2011). Osteo-progenitors in vascular calcification: a circulating cell theory. J Atheroscler Thromb 18:551-559.
18. Fadini GP, M Rattazzi, T Matsumoto, T Asahara and S Khosla. (2012). Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation 125:2772-2781.
19. Fernandez M, V Simon, G Herrera, C Cao, FH Del and JJ Minguell. (1997). Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Transplant 20:265-271.
20. Zvaifler NJ, L Marinova-Mutafchieva, G Adams, CJ Edwards, J Moss, JA Burger and RN Maini. (2000). Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2:477-488.
21. Kuznetsov SA, MH Mankani, S Gronthos, K Satomura, P Bianco and PG Robey. (2001). Circulating skeletal stem cells. J Cell Biol 153:1133-1140.
22. Huss R, C Lange, EM Weissinger, HJ Kolb and K Thalmeier. (2000). Evidence of peripheral blood-derived, plastic-adherent CD34(-/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics. Stem Cells 18:252-260.
23. Rochefort GY, B Delorme, A Lopez, O Herault, P Bonnet, P Charbord, V Eder and J Domenech. (2006). Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 24:2202-2208.
24. Otsuru S, K Tamai, T Yamazaki, H Yoshikawa and Y Kaneda. (2008). Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 26:223-234.
25. Wan M, C Li, G Zhen, K Jiao, W He, X Jia, W Wang, C Shi, Q Xing, et al. (2012). Injury-activated TGFbeta controls mobilization of MSCs for tissue remodeling. Stem Cells 30:2498-2511.
26. Wojakowski W, U Landmesser, R Bachowski, T Jadczyk and M Tendera. (2011). Mobilization of stem and progenitor cells in cardiovascular diseases. Leukemia 26: 23-33.
27. Krankel N, G Spinetti, S Amadesi and P Madeddu. (2011). Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol Ther 129:62-81.
28. Schraufstatter IU, RG Discipio and S Khaldoyanidi. (2011). Mesenchymal stem cells and their microenvironment. Front Biosci 17:2271-2288.
29. Caplan AI and D Correa. (2011). The MSC: an injury drugstore. Cell Stem Cell 9:11-15.
30. Tang Y, X Wu, W Lei, L Pang, C Wan, Z Shi, L Zhao, TR Nagy, X Peng, et al. (2009). TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757-765.
31. Jones CP, SC Pitchford, CM Lloyd and SM Rankin. (2009). CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airways remodeling. Stem Cells 27: 3074-3081.
32. Lazarus HM, SE Haynesworth, SL Gerson and AI Caplan. (1997). Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections. J Hematother 6:447-455.
33. Brouard N, R Driessen, B Short and PJ Simmons. (2010). G-CSF increases mesenchymal precursor cell numbers in the bone marrow via an indirect mechanism involving osteoclast-mediated bone resorption. Stem Cell Res 5: 65-75.
34. Jian B, N Narula, QY Li, ER Mohler, III and RJ Levy. (2003). Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75:457-465.
35. Trion A and LA van der. (2004). Vascular smooth muscle cells and calcification in atherosclerosis. Am Heart J 147:808-814.
36. Watson KE, K Bostrom, R Ravindranath, T Lam, B Norton and LL Demer. (1994). TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 93:2106-2113.
37. Grainger DJ, JC Metcalfe, AA Grace and DE Mosedale. (1998). Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci 111(Pt 19):2977-2988.
38. Towler DA, M Bidder, T Latifi, T Coleman and CF Semenkovich. (1998). Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 273:30427-30434.
39. Mendez-Ferrer S, TV Michurina, F Ferraro, AR Mazloom, BD Macarthur, SA Lira, DT Scadden, A Ma'ayan, GN Enikolopov and PS Frenette. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466:829-834.
40. Tanaka K, M Sata, T Natori, JR Kim-Kaneyama, K Nose, M Shibanuma, Y Hirata and R Nagai. (2008). Circulating progenitor cells contribute to neointimal formation in nonirradiated chimeric mice. FASEB J 22:428-436.
41. Jiang Q, R Oldenburg, S Otsuru, AE Grand-Pierre, EM Horwitz and J Uitto. (2010). Parabiotic heterogenetic pairing of Abcc6-/-/Rag1-/-mice and their wild-type counterparts halts ectopic mineralization in a murine model of pseudoxanthoma elasticum. Am J Pathol 176:1855-1862.
42. Kotani M, J Kikuta, F Klauschen, T Chino, Y Kobayashi, H Yasuda, K Tamai, A Miyawaki, O Kanagawa, M Tomura and M Ishii. (2013). Systemic circulation and bone recruitment of osteoclast precursors tracked by using fluorescent imaging techniques. J Immunol 190:605-612.
43. Cheng SL, JS Shao, LR Halstead, K Distelhorst, O Sierra and DA Towler. (2010). Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/betacatenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res 107:271-282.
44. Shao JS, SL Cheng, JM Pingsterhaus, N Charlton-Kachigian, AP Loewy and DA Towler. (2005). Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115:1210-1220.
45. Wan M, C Yang, J Li, X Wu, H Yuan, H Ma, X He, S Nie, C Chang and X Cao. (2008). Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 22:2968-2979.
46. Wu X, L Pang, W Lei, W Lu, J Li, Z Li, FJ Frassica, X Chen, M Wan and X Cao. (2010). Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 7:571-580.
47. Yu B, X Zhao, C Yang, J Crane, L Xian, W Lu, M Wan and X Cao. (2012). Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling. J Bone Miner Res 27: 2001-2014.
48. Flanders KC, NL Thompson, DS Cissel, E Van Obberghen-Schilling, CC Baker, ME Kass, LR Ellingsworth, AB Roberts and MB Sporn. (1989). Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes. J Cell Biol 108:653-660.
49. Williams AO, KC Flanders and U Saffiotti. (1993). Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer. Am J Pathol 142: 1831-1840.
50. Barcellos-Hoff MH, EJ Ehrhart, M Kalia, R Jirtle, K Flanders and ML Tsang. (1995). Immunohistochemical detection of active transforming growth factor-beta in situ using engineered tissue. Am J Pathol 147:1228-1237.
51. Li C, Q Xing, B Yu, H Xie, W Wang, C Shi, JL Crane, X Cao and M Wan. (2013). Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J Bone Miner Res 28:2094-2108.
52. Dasch JR, DR Pace, W Waegell, D Inenaga and L Ellingsworth. (1989). Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142:1536-1541.
53. Kretzschmar M and J Massague. (1998). SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 8:103-111.
54. Massague J and YG Chen. (2000). Controlling TGF-beta signaling. Genes Dev 14:627-644.
55. Feng XH and R Derynck. (2005). Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 21:659-693.
56. Derynck R. (1994). TGF-beta-receptor-mediated signaling. Trends Biochem Sci 19:548-553.
57. Lee MK, C Pardoux, MC Hall, PS Lee, D Warburton, J Qing, SM Smith and R Derynck. (2007). TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26:3957-3967.
58. Yamashita M, K Fatyol, C Jin, X Wang, Z Liu and YE Zhang. (2008). TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 31:918-924.
59. Xian L, X Wu, L Pang, M Lou, CJ Rosen, T Qiu, J Crane, F Frassica, L Zhang, et al. (2012). Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18:1095-1101.
60. Crane JL and X Cao. (2014). Function of matrix IGF-1 in coupling bone resorption and formation. J Mol Med (Berl) 92:107-115.
61. Annes JP, JS Munger and DB Rifkin. (2003). Making sense of latent TGFbeta activation. J Cell Sci 116:217-224.
62. Thompson B and DA Towler. (2012). Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 8:529-543.
63. London GM. (2012). Bone-vascular cross-talk. J Nephrol 25:619-625.